Loading patent…
OwnerMahesh Vithalbhai Patel, Shrikant Vinayak Gupte +4inventors
InventorsMahesh Vithalbhai Patel, Shrikant Vinayak Gupte, Sachin Subhash Bhagwat, Mohammad Alam Jafri, Girish Kumar Jain, Mandar Madhukar Kodgule
Estimating the term…
The invention relates to an improved therapy for treating resistant bacterial infections caused by extended-spectrum β-lactamase (ESBLs)-producing strains in a warm-blooded animal, adjuvant step down therapy, and pharmaceutical compositions for such therapies. The invention also relates to a method for inhibiting bacterial resistance in ESBLs-producing strains so as to have better control over the therapy; achieve reduced hospital stay and adjuvant step down therapy so as to avoid recrudescence. In particular, the therapy includes antibacterial combination of cefepime with sulbactam via parenteral route, followed by oral third generation cephalosporin with a suitable β lactamase inhibitor.
A method of inhibiting bacterial infections caused by resistant Extended-spectrum β-lactamase producing strains (ESBLs) in a warm blooded animal, the method comprising administering a combination of 2 gm of cefepime and 0.1-4 gm of sulbactam to the warm blooded animal.
A pharmaceutical composition comprising 2 gm of cefepime in combination with 0.1-4 g of sulbactam, and one or more pharmaceutically acceptable excipients.
A method of treating a resistant bacterial infection caused by Extended-spectrum β-lactamase producing strains (ESBLs) in a warm blooded animal, the method comprising providing a dosage form to the warm blooded animal comprising cefepime in combination with sulbactam via parenteral route, followed by providing a dosage form that includes an oral third generation cephalosporin with a suitable β lactamase inhibitor.
Dependencies are inferred from the claim text.